Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Mar
10
2023
Ramifications of FDA’s Proposed Action Levels for Heavy Metals in Baby Food Womble Bond Dickinson (US) LLP
Mar
10
2023
HHS Argues Pharmaceutical Proposal Involves Quid Pro Quo Exchanges ArentFox Schiff LLP
Mar
10
2023
Update: Letter to Powdered Infant Formula Industry Keller and Heckman LLP
Mar
9
2023
Leader of International Drug Trafficking Organization Pleads Guilty to Cocaine Trafficking Conspiracy The U.S. Department of Justice
Mar
9
2023
Real or Not Real? The Difference Between Legal Delta-8/Delta-10 THC and Illegal Delta-8/Delta-10 THCO Bradley Arant Boult Cummings LLP
Mar
9
2023
Patent Law Principles Apply to Claim Scope: Orange Book Delisting and Listing and Regulations McDermott Will & Emery
Mar
8
2023
This Week in 340B: February 28 – March 6, 2023 McDermott Will & Emery
Mar
8
2023
The FDA’s Proposed Rule on Food Labeling: Nutrient Content Claims and Definition of ‘‘Healthy’’ Stubbs Alderton & Markiles, LLP
Mar
8
2023
The Cannabis Paradox: Clarifying the Confusing Legality of Delta-8, THC-O, THCV, and Synthetically Derived THC Stark & Stark
Mar
7
2023
HHS-OIG Foregoes Sanctions On Drug Manufacturer For Providing Free Drugs To Patients Waiting For Insurance Authorization Barnes & Thornburg LLP
Mar
7
2023
DEA Proposes Rule for Post-PHE Telemedicine Sheppard, Mullin, Richter & Hampton LLP
Mar
7
2023
FDA Launches Dietary Supplement Ingredient Directory Keller and Heckman LLP
Mar
7
2023
Comments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 2023 Epstein Becker & Green, P.C.
Mar
7
2023
The Wait is Over . . . Or Is It? DEA’s Proposed Rules Around Telemedicine Prescribing: Initial Impressions and Key Takeaways Epstein Becker & Green, P.C.
Mar
7
2023
EPA Announces Both EPA and FDA to Conduct Virtual Public Meeting and Request Comments on Modernizing Their Approach to Oversight of Certain Products Bergeson & Campbell, P.C.
Mar
6
2023
Old North State Report – March 6, 2023 Nelson Mullins
Mar
6
2023
Federal Circuit Affirms Delisting of REMS System Patent from FDA Orange Book Mintz
Mar
6
2023
Update on FDA’s Prevention Strategies to Enhance Food Safety Keller and Heckman LLP
Mar
4
2023
NIOSH Announces Publication of Article on the Results of 2019 Survey of Engineered Nanomaterial Occupational Health and Safety Practices Bergeson & Campbell, P.C.
Mar
3
2023
Justice Department Announces Application Form for Marijuana Pardon Certificates The U.S. Department of Justice
Mar
3
2023
FDA Issues Draft Guidance on Labeling of Plant-Based Milk Alternatives Epstein Becker & Green, P.C.
Mar
3
2023
DEA Proposes Limited Post-PHE Telemedicine Prescription of Controlled Substances McDermott Will & Emery
Mar
2
2023
The Health AI Frontier: New Opportunities for Innovation Across the Health Care Sector Foley & Lardner LLP
Mar
2
2023
FDA Withdraws Proposed Rule on General Principles for Food Standards Modernization Keller and Heckman LLP
Mar
2
2023
Consumer Fraud PFAS Cases Continue To Rise CMBG3 Law
Mar
1
2023
North Carolina Senate Passes Compassionate Care Act – at Exactly 4:20 p.m.
Mar
1
2023
Desperate Times, Desperate Measuring Cups – FTC Brings Enforcement Action for False “Made in USA” Advertising ArentFox Schiff LLP
Mar
1
2023
Unpacking Averages: Exploring New Data on FDA Responses to FOIA Requests Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins